

ICD - 0 - 3
Carcinoma, infiltrating duct, NOS 8500/3
Site: Breast, NOS C50.9 1/21/11 *mu*

Procedure Date:
Procedure Physician:
Attending Physician/Copies To:

UUID:E66D3DF8-1605-4EFD-AAFA-74F82366FD16
TCGA-BH-A1ET-01A-PR Redacted



PATIENT HISTORY:

* DATE of LMP: *
DATE OF LAST DELIVERY: *
PRE-OP DIAGNOSIS: CANCER LEFT BREAST
POST-OP DIAGNOSIS: SAME
OPERATIVE PROCEDURE: LEFT SEGMENTAL MAST, LEFT AXILLARY DISS
CLINICAL HISTORY: *
MATERIAL SUBMITTED: A) LEFT BREAST BIOPSY/MASS/SEGMENTAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE
B) LEFT AXILLARY LYMPH NODE(S), PROCUREMENT BY SURGICAL PROCEDURE

ADDENDA:

Addendum

MACROSCOPIC DESCRIPTION: Block "A2" for ER/PR and HER-2/neu

FINAL DIAGNOSIS:

ER/PR RESULTS

IMMUNOPEROXIDASE IDENTIFICATION OF ESTROGEN AND PROGESTERONE RECEPTORS IS CARRIED OUT ON SLIDE "A2".
DISTINCT INTRANUCLEAR STAINING IS IDENTIFIED FOR ESTROGEN RECEPTOR (95%) AND PROGESTERONE RECEPTOR (80%).
THEREFORE, BOTH ARE INTERPRETED AS POSITIVE.

HER-2/NEU RESULTS

AS PER THE REQUEST OF DR. BAFFONI, c-erbB2 (HER-2/NEU) IMMUNOSTAINING IS CARRIED OUT ON PREVIOUS MAGEE
BLOCK "A2" (BREAST CANCER) USING A 1:300 DILUTION OF DAKO'S POLyclonal ANTIBODY A485
(DIRECTED AGAINST THE INTRACELLULAR DOMAIN OF c-erbB2) WITHOUT ANTIGEN RETRIEVAL. NO DISTINCT COMPLETE
MEMBRANE STAINING IS IDENTIFIED. THEREFORE, c-erbB2 (HER-2/NEU) IS INTERPRETED AS NEGATIVE (SCORE 0).

FINAL DIAGNOSIS:

FINAL DIAGNOSIS:

A) LEFT BREAST, SEGMENTAL MASTECTOMY:

- INFILTRATING MODERATELY DIFFERENTIATED DUCT CARCINOMA WITH FOCAL LOBULAR FEATURES. 2.0 CM. (AS MEASURED ON
GLASS SLIDE), POOR ARCHITECTURAL GRADE, INTERMEDIATE NUCLEAR GRADE (NOTTINGHAM SCORE=6, TUBULES=3, MITOTIC
RATE=1, NUCLEAR PLEOMORPHISM=2) (SEE NOTE) (CROSS REFER *[redacted]*)
- FIBROCYSTIC CHANGES WITH ATYPICAL DUCTAL EPITHELIAL HYPERPLASIA
- PAPILLOMATOSIS WITH ASSOCIATED MICROCALCIFICATIONS
- MARGINS OF RESECTION ARE FREE OF TUMOR

B) LEFT AXILLARY CONTENTS:

- ONE OF NINETEEN (1/19) LYMPH NODES POSITIVE FOR METASTATIC CARCINOMA

NOTE: ER/PR immunoperoxidase assay and Her-2/NEU testing will be performed on block "A2".

Criteria	Yes	No
Diagnosis Discrepancy	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Primary/Tumor Site Discrepancy	<input checked="" type="checkbox"/>	<input type="checkbox"/>
HIPAA Discrepancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Prior Malignancy History	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Dual/Synchronous Primary Malignancy	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Case is (circle): <input checked="" type="checkbox"/> CONFIRMED / <input type="checkbox"/> DISQUALIFIED		
Reviewer Initials: <i>[initials]</i>	Date Reviewed: <i>[date]</i>	